1537 POSTER No change of health related quality of life in the Norwegian general population across an 8 year period

2005 ◽  
Vol 3 (2) ◽  
pp. 447
Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1500 ◽  
Author(s):  
Rebecca V. Steenaard ◽  
Laura A. Michon ◽  
Harm R. Haak

Insight into the health-related quality of life (HRQoL) impact of adrenocortical carcinoma (ACC) is important. The disease and its treatment options potentially have an impact on HRQoL. For patients with limited survival, HRQoL research is of utmost importance. We will therefore provide an overview of HRQoL studies in patients with ACC. We found six studies that measured HRQoL in 323 patients with ACC (3 cross-sectional, 1 cohort, 2 trials), all indicating a reduced HRQoL compared to the general population. The FIRMACT trial found that HRQoL of patients with ACC was reduced compared to the general population, and that chemotherapy-mitotane further reduced HRQoL even though survival improved. Clinical aspects of the disease, including cortisol and aldosterone production and adrenal insufficiency have shown great impact on HRQoL in benign disease, even after the recovery of hormonal status. However, the impact of malignant adrenal disease and treatment options on HRQoL including adrenalectomy, radiotherapy, mitotane therapy, and chemotherapy have not been sufficiently studied in patients with ACC. Although the number of HRQoL studies in patients with ACC is limited, the existing literature does indicate that ACC has a large impact on patients’ HRQoL, with disease specific aspects. Further HRQoL research in patients with ACC is essential to improve patient-centered care, preferably by using an ACC-specific HRQoL questionnaire.


PeerJ ◽  
2013 ◽  
Vol 1 ◽  
pp. e98 ◽  
Author(s):  
Robert Johansson ◽  
Per Carlbring ◽  
Åsa Heedman ◽  
Björn Paxling ◽  
Gerhard Andersson

2010 ◽  
Vol 120 (1-3) ◽  
pp. 126-132 ◽  
Author(s):  
Mascha C. ten Doesschate ◽  
Maarten W.J. Koeter ◽  
Claudi L.H. Bockting ◽  
Aart H. Schene

Circulation ◽  
2019 ◽  
Vol 139 (Suppl_1) ◽  
Author(s):  
Marialaura Bonaccio ◽  
Augusto Di Castelnuovo ◽  
Simona Costanzo ◽  
Amalia De Curtis ◽  
Mariarosaria Persichillo ◽  
...  

2015 ◽  
Vol 25 (suppl_3) ◽  
Author(s):  
L Scalone ◽  
PA Cortesi ◽  
LG Mantovani ◽  
R Ciampichini ◽  
G Cesana

2020 ◽  
Vol 30 (03) ◽  
pp. 273-278
Author(s):  
Gabrielle Derraugh ◽  
Suyin A. Lum Min ◽  
Richard Keijzer

AbstractThe health-related quality of life (HRQoL) of survivors of congenital diaphragmatic hernia (CDH) is presently unknown. Literature prior to 2015 suggests that CDH survivors have worse HRQoL compared with the general population. However, due to changes in the diagnosis, management, and follow-up of CDH patients, this may no longer be true. The objective of this review was to determine what recent literature suggests regarding the HRQoL of CDH survivors. We reviewed all studies published between April 9, 2015, and April 6, 2020, that described the HRQoL of CDH survivors. Studies were identified using PubMed, and the references of the identified papers were searched for additional studies eligible for inclusion. Seven studies describing HRQoL in CDH survivors using validated measures of HRQoL for children, PedsQL (Pediatric Quality of Life Inventory), KIDSCREEN-52, and Comprehensive Quality of Life Scale – School Version were examined. The findings were disparate. One study suggested that CDH survivors had better than average HRQoL scores, three studies found patients and controls had equivalent scores, and two studies reported poor outcomes for CDH patients. The final study found no effect of disease severity on HRQoL, as determined by prenatal ultrasound. Evidence published between 2015 and 2020 suggests that CDH patients have an HRQoL equivalent to the general population.


Sign in / Sign up

Export Citation Format

Share Document